Figure 6.

EpEX increases the binding of HMGA2 and EpICD to the promoter of Oct4 and Sox2. MSCs were treated with the EGF inhibitor AG1478 and then treated with EpEX (3 μg/ml) and EGF (50 nm). Binding of HMGA2 to the Oct4 (A) and Sox2 (B) promoter was examined by ChIP. HMGA2 was pulled down by a specific anti-HMGA2 antibody. The cross-linked DNA was isolated and then probed by qPCR with specific primers for the Oct4 and Sox2 promoter. MSCs were treated with EGF inhibitor AG1478 and then treated with EpEX (3 μg/ml) and EGF (50 nm). Binding of HMGA2–EpICD was examined by sequential ChIP. EpICD was pulled down by a specific anti-EpICD antibody, followed by pulldown with a HMGA2 antibody. To detect bound Oct4 (C) and Sox2 (D) promoter, the cross-linked DNA was isolated and then amplified by qPCR with specific primers. N.D., not detected. Data represent the mean ± S.D. *, p < 0.05, compared with control without EGF, EpEX, and AG1478 group.